Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
Molnupiravir, a repurposed flu antiviral with a poor history, delivers in a pivotal study in Covid-19 outpatients.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Drugs prompting the most divergent opinions on outlook include Pfizer and Vir’s Covid-19 offerings and Biogen’s Aduhelm.
But is there room for another antibody, given lacklustre sales and Regeneron’s dominance?
The Junshi/Coherus drug only beat chemotherapy, and its study was run not in the US but in China.